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ABSTRACT
The tumor suppressor gene HIC1 (Hypermethylated In Cancer 1) encodes
a transcriptional repressor mediating the p53-dependent apoptotic response to
irreparable DNA double-strand breaks (DSBs) through direct transcriptional repression
of SIRT1. HIC1 is also essential for DSB repair as silencing of endogenous HIC1 in BJhTERT fibroblasts significantly delays DNA repair in functional Comet assays. HIC1
SUMOylation favours its interaction with MTA1, a component of NuRD complexes.
In contrast with irreparable DSBs induced by 16-hours of etoposide treatment, we
show that repairable DSBs induced by 1 h etoposide treatment do not increase HIC1
SUMOylation or its interaction with MTA1. Furthermore, HIC1 SUMOylation is dispensable
for DNA repair since the non-SUMOylatable E316A mutant is as efficient as wt HIC1
in Comet assays. Upon induction of irreparable DSBs, the ATM-mediated increase of
HIC1 SUMOylation is independent of its effector kinase Chk2. Moreover, irreparable
DSBs strongly increase both the interaction of HIC1 with MTA1 and MTA3 and their
binding to the SIRT1 promoter. To characterize the molecular mechanisms sustained
by this increased repression potential, we established global expression profiles of BJhTERT fibroblasts transfected with HIC1-siRNA or control siRNA and treated or not with
etoposide. We identified 475 genes potentially repressed by HIC1 with cell death and
cell cycle as the main cellular functions identified by pathway analysis. Among them,
CXCL12, EPHA4, TGFβR3 and TRIB2, also known as MTA1 target-genes, were validated
by qRT-PCR analyses. Thus, our data demonstrate that HIC1 SUMOylation is important
for the transcriptional response to non-repairable DSBs but dispensable for DNA repair.

INTRODUCTION

or predispose to oncogenic transformation if misrepaired.
To cope with these lesions, cells have developed multiple
interacting pathways called the DNA damage response
(DDR) that lead either to damage repair or to programmed
cell death depending on the extent of the damage [1]. A
multi-branched, highly coordinated signaling cascade
of Post-Translational Modifications (PTM) allows the

The genomic integrity of all living organisms
is constantly challenged by deleterious attacks due to
endogenous or exogenous genotoxic stress. DNA damage
and in particular DNA double-strand breaks (DSBs) are
highly deleterious since they can be lethal if unrepaired
www.impactjournals.com/oncotarget
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effective recruitment, stabilization and retention at DSBs
of numerous proteins including sensors, mediators and
effectors of the DDR [2]. A major transducer of DNA
damage signaling in the case of DSBs is the activation
of the PIKKs (Phosphatidylinositol 3 kinase-like protein
kinase) ATM or DNA-PKcs proteins. In particular, the
apical ATM kinase phosphorylates hundreds of proteins
including histones (H2AX), repair factors (BRCA1),
its effector kinase (CHK2) or transcription factors such
as P53 [3]. Previous studies demonstrated that together
with P53, SIRT1 and the tumor suppressor gene HIC1
(Hypermethylated in cancer 1), which is epigenetically
silenced by promoter hypermethylation in many types
of human cancers [4, 5], plays a critical role in the DNA
damage response [6–8]. Indeed, HIC1 is a direct targetgene of P53 and upon induction of irreparable DSBs,
HIC1 regulates the p53-dependant apoptotic DNA damage
response [6]. When treated overnight with etoposide,
a DSB inducer, wt Murine Embryo Fibroblasts (MEFs)
rapidly begin to die whereas Hic1–/– MEFs are resistant
to apoptosis. Conversely, re-expression of HIC1 in MCF-7
cells through adenoviral infection restores their sensitivity
to P53-induced apoptosis [6]. This effect relies mainly on
the HIC1-mediated direct transcriptional repression of
SIRT1, which deacetylates and inactivates P53 allowing
cells to by-pass P53 induced apoptosis and survive DNA
damage [6]. Recently, we have shown that HIC1 is also
a key player in the response to repairable DNA damage.
Down-regulation of endogenous HIC1 expression through
RNA interference in normal human fibroblasts treated for
1 hour with Etoposide delays DNA repair, as shown by
functional comet assays [8].
HIC1 encodes a transcriptional repressor containing
an N-terminal BTB domain and five C-terminal C2H2
Krüppel-like Zinc fingers [9] We have shown that HIC1
interacts with 4 major co-repressors complexes involved
in chromatin remodelling and epigenetic regulation;
CtBP, SWI/SNF, NuRD and the Polycomb PRC2
complex [9]. In particular, we have demonstrated through
yeast two-hybrid screening and various biochemical
approaches that HIC1 interacts with the C-terminal
region of MTA1, a core component of NuRD, through
a SUMOylation consensus motif in the HIC1 central
region [10, 11]. SUMOylation is a highly dynamic and
labile PTM that plays a key role in the assembly of multiprotein complexes [12]. The HIC1-MTA1 interaction is
regulated by two mutually exclusive PTM of Lysine 314,
promotion by SUMOylation and inhibition by acetylation
[10, 11]. Previously, we demonstrated that irreparable
DSBs induced by a 16 h treatment with etoposide
result in a specific increase of HIC1 SUMOylation in
an ATM-dependant manner [8]. This increase of HIC1
SUMOylation is correlated with an increased interaction
of endogenous HIC1 and MTA1 proteins in etoposide
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treated normal human fibroblasts, thereby favouring the
recruitment of NuRD repressive complexes onto HIC1
target genes [8]. This provides the first mechanism by
which the transcriptional repression function of HIC1 is
activated upon DNA damage.
In this study, we further investigated the function and
regulation of HIC1 SUMOylation during the DNA damage
response to repairable and non-repairable DSBs. First, we
demonstrate that HIC1 SUMOylation does not increase
upon induction of repairable DSBs by a 1 h etoposide
treatment. In addition, results from functional DNA
repair assays such as Comet assays using overexpression
of wt or non-SUMOylatable (E316A) HIC1 in Cos-7
cells that do no express endogenous HIC1 demonstrated
that SUMOylation on Lysine 314 is not implicated in
DSB repair. Indeed, the efficiency and kinetics of repair
exhibited by the E316A point mutant and wild-type HIC1
are virtually indistinguishable. Furthermore, we show
that the increased SUMOylation of HIC1 in the presence
of irreparable DSBs induced by a 16 hours etoposide
treatment is primarily dependent on ATM which is
stabilized and activated on chromatin but independent
of its nucleoplasmic effector kinase CHK2. As for the
HIC1-MTA1 interaction, we showed that it depends on
a non-covalent interaction between SUMOylated HIC1
and the SUMO-interacting motif (SIM) in the C-terminal
part of MTA1. Furthermore, we demonstrated that HIC1
also interacts with the related corepressor MTA3 and that
irreparable DSBs increase this interaction, as shown for
MTA1. By ChIP experiments, we showed that induction
of irreparable DSBs results in an increased recruitment
of MTA1, MTA3 and also of HIC1 onto HIC1-response
elements (HiRE) in the SIRT1 promoter. To further
characterize the molecular mechanisms sustained by
this increased repression potential, we established global
expression profiles of BJ-hTERT fibroblasts transfected
with HIC1-siRNA or control siRNA and treated or not
with etoposide. We identified 475 genes potentially
repressed by HIC1 with cell death and cell cycle as the
main cellular functions identified by pathway analysis.
Cross referencing this list with the 1024 MTA1 target
genes identified by comparing wt MEFs (Murine
Embryos Fibroblasts) with Mta1 –/– MEFs identified 17
common genes. Among them, CXCL12, EPHA4, LPHN2,
TGFβR3 and TRIB2 were shown to be activated in siHIC1
fibroblasts and to be more repressed in control cells treated
with Etoposide to increase HIC1 SUMOylation.
In summary, our results demonstrate that HIC1
SUMOylation is dispensable for DNA repair but is
important for the p53-dependent apoptotic transcriptional
response to irreparable DSBs, notably through the
recruitment of MTA1 or MTA3 containing NuRD
repressive complexes to the SIRT1 promoter and other
potential direct target genes.
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RESULTS

clearly failed to demonstrate a stronger interaction
between these two proteins (Figure 1D).
In conclusion, repairable and non-repairable
DSBs, induced by 1 hour or 16 hours etoposide
treatments respectively, have different impacts on HIC1
SUMOylation and hence on the interaction between
HIC1 and the NuRD complex, potentially in line with
the biological outcomes of the DNA damage responses to
these different genotoxic insults, repair or apoptosis.

Repairable DNA DSBs do not result in a PIKKdependant increase of HIC1 SUMOylation and
interaction with MTA1
We previously demonstrated that induction of
non-repairable DSBs by overnight (16 h) treatment of
transfected HEK293T cells with 20 μM etoposide, an
inhibitor of topoisomerase II known to induce DSBs,
results in a significant increase of HIC1 SUMOylation [8].
Such a prolonged assault leads to the accumulation of nonrepairable damage resulting in a p53-dependent apoptotic
response [6]. HEK293T cells were transfected with the
empty FLAG or FLAG-HIC1 expression vectors with or
without an expression vector for His-SUMO2 and/or the
de-SUMOylase SENP2. 48 hours after transfection, cells
were treated with 20 μM etoposide for 16 hours to induce
non-repairable DNA damage and immediately lysed
under denaturing conditions. Total extracts were then
analyzed by Western blot with anti-FLAG monoclonal
antibodies to detect HIC1 and its SUMOylated forms.
As shown in Figure 1A, the isoform of higher molecular
weight, corresponding to the SUMOylated form of HIC1,
disappeared in presence of SENP2 and is significantly
increased after 16 h etoposide treatment, as previously
shown [8].
Since endogenous HIC1 also activates the kinetics
and/or efficiency of DSB repair in BJ-hTERT fibroblasts,
we next wanted to address the importance of HIC1
SUMOylation in the repair process [8]. In striking contrast
with the ATM-dependent increase of HIC1 SUMOylation
observed in HEK293T cells treated for 16 hours with
etoposide [8], HIC1 SUMOylation levels do not increase
after the induction of repairable DSBs by a short (1 hour)
etoposide treatment (Figure 1B, compare lanes 3 and
4 to lanes 7 and 8). This HIC1 SUMOylation is also
independent of ATM activation since its level remains
constant when cells are pre-incubated for 1 h with the
specific ATM inhibitor Ku-55939 prior to the 1 hour
etoposide treatment (Supplementary Figure S1A).
DNA-damaging agents that create DSBs activate
a DDR primarily relying on the activation of kinases of
the PIKKs (Phosphatidylinositol 3 kinase-like protein
kinase) family, ATM or DNA-PKcs proteins [13]. After
induction of repairable damage, inhibition of ATM
and DNA-PKcs by Wortmaninn, a PI3K inhibitor also
inhibiting PIKKs, or by pharmacological inhibitors
specific for each PIKK, has no significant effects on HIC1
SUMOylation (Figure 1C). Previously, we demonstrated
that SUMOylation potentiates the repressive potential
of HIC1 by favoring its interaction with MTA1 [10, 11],
most notably during the response to non-repairable DSBs
[8]. However, after induction of repairable DSBs, coimmunoprecipitation experiments in HEK293T cells
transfected with expression vectors for HIC1 and MTA1
www.impactjournals.com/oncotarget

Lack of HIC1 SUMOylation does not impair
DNA repair
To address the functional impact of HIC1
SUMOylation on the time-course of DSBs repair, we first
tested wt HIC1 and the empty FLAG expression vector
in the neutral Comet assay which specifically measured
DSBs at the level of individual cells. To that end, 48
hours after transfection, Cos7 cells which do not express
HIC1 at significant endogenous levels were treated for 1
hour with etoposide before recovery in complete culture
medium without etoposide for various times. As shown in
Figure 2A, ectopic expression of HIC1 slightly accelerates
DSBs repair notably during the early steps of recovery (2 h
and 4 h). These observations are in close agreement with
the slower repair induced in BJ-hTERT human fibroblasts
by inactivation of endogenous HIC1 expression through
siRNA interference [8]. We next compared the DNA repair
capacity of HEK293T cells transfected with wt HIC1 or
with the non SUMOylatable E316A point mutant. HIC1
Lysine 314 can be acetylated and SUMOylated [10, 11].
Therefore, we used the E316A mutant (non SUMOylatable
since the SUMOylation consensus is ϕKxE) instead of
the K314R mutant since this latter would impede not
only SUMOylation but also acetylation or any other
potential post-translational modifications on this lysine
residue [14]. Results showed that the same amount of
DSBs were induced in HEK293T transfected with the two
expression vectors. Furthermore, no salient differences
were observed during the time-course recovery in normal
medium of cells expressing the wt or the E316A SUMOdeficient HIC1 mutant (Figure 2B–2D). Thus, these results
unambiguously demonstrate that HIC1 SUMOylation on
lysine K314 is not essential for DSBs repair.

HIC1 SUMOylation increase after 16 h etoposide
treatment is dependent of ATM
DSBs elicit a DNA damage response primarily
relying on the activation of the ATM or DNA-PKcs
kinases which have complementary and non-redundant
functions [13, 15]. Whereas ATM has hundreds of
substrates, DNA-PKcs phosphorylates a smaller group of
proteins involved in DSBs end joining. [16]. We tried to
inhibit ATM and DNA-PKcs by a 1 hour pre-treatment
with Wortmaninn or with specific pharmacological
2918
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Figure 1: Repairable DNA double-strand breaks (DSBs) induced by a 1 hour etoposide treatment do not lead to
an ATM-dependent increase of HIC1 SUMOylation. (A) Etoposide-induced non-repairable DSBs lead to an increase of HIC1

SUMOylation. HEK293T cells were transfected with the indicated combination of empty FLAG, FLAG-HIC1, SENP2 and SUMO2
expression vectors. 32 hours after transfection cells were incubated for 16 hours with 20 μM etoposide (+) or DMSO (–) as control before
direct lysis in denaturing conditions. Total cell extracts were analyzed by Western Blotting (WB) using the indicated antibodies. (B) HEK
293T cells were transfected with FLAG-HIC1 and treated with etoposide or DMSO for 1 hour or 16 hours. Cell extracts were prepared
as described in panel A) and analyzed by immunoblotting using the indicated antibodies. Quantification of SUMO-HIC1 to total HIC1
(FLAG) was performed with the Fujifilm MultiGauge software (Bottom Panel) (C) HEK 293T cells were transfected with FLAG-HIC1
and treated with etoposide or DMSO for 1 hour. Transfected cells were pre-treated or not with the following inhibitors (Wortmannin;
ATMi, ATM inhibitor and DNAPKcsi, DNA-PKcs inhibitor) 1 hour before etoposide treatment, as indicated. Cell extracts were prepared
as described in panel B) and analyzed by immunoblotting using the indicated antibodies. (D) HEK293T cells were co-transfected with the
indicated combinations of expression vectors for FLAG-HIC1 and MTA1 and then incubated for 1 hour in etoposide or with DMSO as
control. After lysis in IPH buffer, cells extracts were co-immunoprecipitated with anti-HIC1 antibodies. The immunoprecipitates as well as
2% of the whole cell extract (Input) were analyzed by Western blotting with the anti FLAG and anti MTA1 antibody. Note that the MTA1
antibodies detect a doublet of endogenous proteins in non transfected cells whereas the ectopically expressed MTA1 protein co-migrates
with the upper band of the doublet (arrowheads).
www.impactjournals.com/oncotarget
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inhibitors for each PIKK prior to a 16 hours etoposide
treatment to induce non-repairable DSBs in the presence
of these inhibitors as previously performed with the ATM
specific inhibitor [8]. However, in these conditions where
the DNA-PKcs inhibitor was kept on the cells for 17
(1+16) hours, a strong cytotoxic effect precluding further
analyses was observed (data not shown). To circumvent
this technical problem, we then used siRNA interference
to inactivate DNA-PKcs or ATM, as a positive control.

Upon induction of irreparable damage, the increase of
HIC1 SUMOylation was observed in cells tranfected with
control siRNAs and also in cells transfected with a pool of
siRNAs efficiently targeting ATM albeit to a lesser extent
(Figure 3A, lanes 1 to 4 and Figure 3B). These findings
therefore nicely confirmed our previous results obtained
with the pharmacological ATM inhibitor, Ku-55933 [8].
Silencing of DNA-PKcs by siRNAs did not fully abolish
the increase of HIC1 SUMOylation but did significantly

Figure 2: HIC1 SUMOylation is not required for efficient DSBs repair. (A) Cos7 cells were transfected for 48 hours with wt

FLAG-HIC1 or with the empty pcDNA3FLAG expression vector. Cells were either mock-treated with DMSO (–) or treated with 20 μM
etoposide (+) for 1 hour. After removal of the drug, cells were allowed to recover in normal medium for various times (2, 4, 6 and 24 hours)
and DSBs were monitored by neutral Comet assay. The percentage of Comet positive cells reflecting unrepaired DNA breaks is depicted
after counting at least 100 cells in each condition. (B) Cos7 cells were transfected for 48 hours with wt FLAG-HIC1 or with the nonSUMOylatable E316A point mutant. Neutral Comet assays were performed and analyzed as described in panel A). The error bar indicates
mean +/– standard deviation of three independent experiments (NS: not significant). (C) Representative Comet images of mock-treated
(DMSO) and of cells treated with etoposide for 1 hour after transfection of wt HIC1 or of E316A HIC1 with or without recovery in normal
medium for 4 and 24 hours, respectively. (D) Western blot analyses of cells transfected with wt HIC1 or with E316A HIC1 Samples of
cells in each condition were taken before the Comet assays and immediately lysed in Laemmli loading buffer. These whole cell extracts
were analyzed by Western blot with anti-FLAG antibodies to detect HIC1 and its SUMOylated forms. γH2AX and actin levels were used
as controls for DSB induction and equal loading, respectively.
www.impactjournals.com/oncotarget
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Figure 3: The SUMOylation increase of HIC1 upon induction of irreparable DSBs is dependent on ATM but
independent of DNA-PKcs. (A) HEK293T cells were transfected either with nontargeted control siRNA (siCtrl), either with a pool

of four siRNAs targeting ATM (siATM) or with a pool of four siRNAs targeting DNAPKcs (siDNAPKcs). The next day, these cells were
transfected with a FLAG-HIC1 expression vector for 24 hours and were then treated with 20 μM etoposide (+) or mock-treated with DMSO
(–) as control for 16 hours before direct lysis in denaturing conditions. Total cell extracts were analyzed by Western Blotting (WB) using
the indicated antibodies. (B) Quantification of SUMO-HIC1. The HIC1 SUMOylated band in control conditions (siCtrl, DMSO 16 h; lane 1
in panel A) was quantified with the Fujifilm MultiGauge software and given the arbitrary value of 1. The other HIC1 SUMOylated bands
(lanes 2 to 6 in panel A) were quantified relative to this value. (C) HEK293T cells were transfected either with nontargeted control siRNA
(siCtrl), a pool of four siRNAs targeting ATM (siATM) or with each individual siRNA from the pool targeting DNA-PKcs (siDNA-PKcs).
Then, cells were treated with etoposide and total cell extracts were analyzed by Western blot on three different gels (two 6% polyacrylamide
gels for DNAPK-cs and ATM; a 15% polyacrylamide gel for γH2AX, H2AX and actin) as described in panel A.
www.impactjournals.com/oncotarget
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impair it to levels similar to those obtained with ATM
siRNAs (Figure 3A, lanes 5 and 6 and Figure 3B).
However, in the control Western blots, we noticed that this
pool of siRNAs targeting DNA-PKcs down regulate not
only the expression of DNA-PKcs but also surprisingly
the expression of ATM (Figure 3A, lanes 5 and 6).
These results were confirmed by qRT-PCR analyses of
ATM expression levels in the same transfected cells
(Supplementary Figure S2). To explain this, we performed
another experiment testing individually the four siRNAs
of the pool targeting DNAPKcs. In Western blots, the three
siRNAs that efficiently inhibit DNA-PKcs expression
(#7, #8 and #9) also inhibit ATM expression whereas the
siRNA DNA-PKcs #6 has no effect on DNAPK-cs and
ATM expression (Figure 3C, lanes 5 to 12). As expected,
the control siRNAs have no effect on ATM and DNAPKcs and the pool of siRNAs targeting ATM has no effect
on DNA-PKcs expression (Figure 3A, lanes 1 to 4). After
a 16 h etoposide treatment, the SUMOylation increase
observed in cells transfected with the ATM siRNAs pool
which express DNA-PKcs and in cells tranfected with
the DNAPK-cs siRNAs pool, in which the expression
of both DNAPK-cs and ATM are severely inhibited,
appears reduced but similar (Figure 3A and 3B). Thus, the
increase of HIC1 SUMOylation observed upon induction
of irreparable DSBs appears to be primarily dependent
upon ATM.

effects on two ATM substrates (T68Chk2 and γH2AX) or
on ATM autophosphorylation (Figure 4A and 4B).
To confirm these results with an independent
assay, we used siRNA interference to inactivate Chk2.
We first demonstrated the efficiency of a pool of
siRNAs (Dharmacon) targeting Chk2 by transfection in
HEK293T grown in standard conditions (no etoposide
treatment) followed by qRT-PCR and Western blot
analyses (Figure 4C and 4D). Using this pool of siRNAs
targeting Chk2, we further showed that the increase of
HIC1 SUMOylation observed after a 16 hour etoposide
treatment is not significantly affected by Chk2 inhibition
(Figure 4D and 4E).
In conclusion, the increase of HIC1 SUMOylation
upon induction of non-repairable DSBs is dependent upon
the apical kinase ATM [8] but not its downstream effector
kinase Chk2. Thus, these results strongly suggest that the
increase of HIC1 SUMOylation occurs and plays a role in
close proximity to chromatin where ATM is activated and
stabilized consistent with the “on-site modification” model
proposed for SUMOylation.

The SIM (SUMO-interacting motif) of MTA1 is
required for the interaction with HIC1
Since the induction of non-repairable DSBs and
the resulting increase in SUMOylation of HIC1 favors
its interaction with MTA1, we further investigated the
molecular mechanisms underpinning the HIC1-MTA1
interaction with a focus on SUMOylation [8, 11]. A
SUMOylated protein can interact non-covalently with
another protein containing a SIM (SUMO-interacting
motif) [14]. MTA1 contains in its C-terminal end a
functional SIM motif DEPIVIED (Figure 5A) perfectly
fitting with the most canonical class of SIM motifs, a
hydrophobic core (V/I)X(V/I)(V/I) flanked by acidic
amino acids [18, 19]. Interestingly, triple mutations in
the hydrophobic core of the SIM motif in MTA1 (I711A/
V712A/I713A, referred to hereafter as AAA) abolished
the interaction of MTA1 with HIC1 (Figure 5B, lane 5).
MTA1 is also SUMOylated on Lysine 509, which is
located in its C-terminal region [19]. However, in contrast
with the AAA SIM mutant, wt MTA1 and the K509R nonSUMOylatable mutant similarly interacted with HIC1 in
co-immunoprecipitation experiments, demonstrating that
MTA1 SUMOylation is not required for this interaction
(Figure 5C, lane 5 and 6).
Thus, the SIM motif of MTA1 is essential for the
interaction with HIC1, in agreement with the fact that
HIC1 SUMOylation favors it, and thus highlights a
SUMO-SIM non-covalent interaction between these two
proteins [11]. However, the region of interaction between
HIC1 and MTA1 previously defined by the prey isolated
in the yeast two-hybrid screening as MTA1 amino-acids
397-473 excluded this MTA1 SIM motif (Figure 5A)

HIC1 SUMOylation increase is dependent on
the apical kinase ATM but independent of its
effector kinase Chk2
After detection of DSBs by sensors such as the
MRN complex, DNA damage signaling is rapidly induced
by the activation of the ATM/Chk2 pathway. Whereas
the apical ATM kinase is recruited to and stabilized
on the DSBs sites, its effector kinase Chk2 becomes
phosphorylated by ATM at damage sites but then rapidly
dissociates and is distributed throughout the nucleus to
phosphorylate numerous downstream targets [2, 17]. To
determine whether the HIC1 SUMOylation increase after
irreparable DSB induction requires the complete activation
of the ATM/Chk2 pathway and is dependent on both ATM
and Chk2 activation, FLAG-HIC1-transfected cells were
pre-incubated with C3742, a specific inhibitor of Chk2,
prior to a 16 hour etoposide treatment (Figure 4A). Both
the basal and enhanced SUMOylation of HIC1 observed
after induction of irreparable DSBs remained unchanged
in presence of the Chk2 inhibitor (Figure 4A, lanes 4 to 8).
Similar results were obtained with cells treated with
etoposide for 1 hour (Supplementary Figure S4). As
controls for the effectiveness of the Chk2 inhibitor, we
observed a strong decrease of Chk2 autophosphorylation
on Serine 516 as well as of phosphorylation of P53 on
Serine 20, a well-known target of Chk2 but no significant

www.impactjournals.com/oncotarget
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Figure 4: The increase of HIC1 SUMOylation upon irreparable DSB induction by etoposide requires ATM but not its
effector kinase Chk2. (A) HEK293T cells were transfected with the FLAG and FLAG-HIC1 vectors. 48 hours after transfection, cells

were pre-incubated or not with the Chk2 inhibitor (Chk2i) for 1 hour and then with etoposide for 16 hours as indicated. Cell extracts were
prepared and Western blotting was performed with the indicated antibodies. *refers to non-specific bands detected by the anti pS516Chk2
(autophosphoylation) and by the anti pS20P53 (Chk2 target) antibodies. γH2AX and actin levels were used as controls for DSBs induction
and equal loading, respectively. (B) To control for the inhibition of Chk2, HEK293T cells were transfected and pre-incubated or not with the
Chk2 inhibitor (Chk2i) for 1 hour and then with etoposide for 16 hours exactly as in panel A) before lysis and Western blot analyses with
the indicated antibodies (C) HEK293T cells grown in normal medium were transfected with siRNA control (siCtrl) or with a Chk2 siRNA
pool (siChk2). Total RNAs were extracted and the mRNA expression levels of Chk2 were assessed by qRT-PCR. Values were normalized
to 18S. (D) HEK293T cells were transfected either with non-target control siRNA (siCtrl) or with a Chk2 siRNA pool (siChk2) before
being transfected with the indicated combination of FLAG, FLAG-HIC1 and SUMO-2 expression vectors. Cells were either incubated with
DMSO (–) or with 20 μM etoposide (+) for 16 hours. Total cell extracts were prepared and analyzed by Western blotting with the indicated
antibodies. *refers to a non-specific band detected by the anti pS516Chk2, used as a control for Chk2 kinase activity. γH2AX and actin
levels were used as controls for DSBs induction and equal loading, respectively. (E) Quantification of SUMO-HIC1 to total HIC1 (FLAG)
for lanes 5 to 8 in panel D) was performed with the Fujifilm MultiGauge software.
www.impactjournals.com/oncotarget
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and the HIC1 K314R non-SUMOylatable mutant still
interacts with MTA1, albeit weakly [11]. To elucidate
this interaction, we constructed another mutant of the
full length HIC1 protein, hereafter referred to as HIC1
ΔMKHEP, by deleting amino acids 305-326 encompassing
this SUMOylation motif. In co-immunoprecipitation
experiments, the ΔMKHEP HIC1 mutant interacts very
weakly with ectopically expressed MTA1 proteins
as compared to wt HIC1 (Figure 5D, lanes 5 and 6).
Furthermore, this deletion mutant upon overexpression in
HEK293T cells is almost unable to co-immunoprecipitate
with endogenous MTA1 proteins (Figure 5E, lane 2).
Reciprocally, we fused the isolated SUMOylation motif
of HIC1 (amino acids 305-326) in frame with a C-terminal
DNA-binding domain, a nuclear localization signal and
an HA epitope in the Gal4-NLS-HA vector to mimic
its localization in the full-length protein. However, this
305-326-HIC1-Gal4 chimera despite being nuclear
and displaying a strong repression potential in transient
Luciferase reporter assays, is unable to significantly
interact with MTA1 (data not shown).
All together these results suggest a complex, multidomain interaction between HIC1 and MTA1 with major,
but not exclusive, roles played by the HIC1 SUMOylation
motif and the MTA1 SUMO-interacting motif.

NuRD complexes and that these repressive complexes are
favoured to repress some HIC1 target genes and notably
SIRT1 during the apoptotic DNA damage response to nonrepairable DSBs.

Differential HIC1 recruitment on the SIRT1
promoter upon induction of repairable versus
non-repairable DSBs
We next compared HIC1 binding of the SIRT1
promoter upon induction of repairable or non-repairable
DSBs. We first performed pilot ChIP experiments with
BJ-hTERT cells treated or not with DMSO (vehicle) or
Etoposide for various times. Whereas HIC1 is bound on
the SIRT1 promoter in control (untreated) conditions, this
binding is slightly decreased in the presence of DMSO,
especially after the longest treatment times (6 hours)
(Figure 7A). ChIP experiments conducted with BJhTERT cells treated for 1 h with Etoposide detected a
clear decrease of HIC1 binding to the SIRT1 promoter
(Figure 7A). By contrast, a strong increase of HIC1
binding is observed upon induction of non-repairable
damage. Notably, SUMOylation of the related BTB/POZ
transcriptional repressor PLZF also increases its DNA
binding properties [23, 24]. In an independent experiment,
HIC1 binding and the recruitment of MTA1 to the SIRT1
promoter were also increased after a 16 hours etoposide
treatment (Figure 7B, left columns). The proneuronal
HIC1 target gene, ATOH1 and GAPDH were used as
controls. Thus, these data demonstrate that the induction
of non-repairable DSBs increased the binding of HIC1 and
its SUMOylation-dependent partners, MTA1 and MTA3,
to the SIRT1 promoter.

HIC1 interacts with MTA3 and this interaction
increases upon induction of non-repairable DSBs
MTA1, the closely related MTA2 and the
functionally distinct MTA3 proteins are found in a
mutually exclusive manner in different specialized NuRD
complexes [20, 21]. Given that HIC1 interacts with MTA1
and this interaction is favoured by HIC1 SUMOylation [8,
11], we thus investigated if HIC1 also interacts with MTA3
and if this interaction increased upon induction of nonrepairable DSBs. Co-immunoprecipitation experiments
(Co-IPs) in transiently transfected HEK293T cells
demonstrated that HIC1 interacts with MTA3 and that this
interaction strongly increased when cells were pre-treated
with etoposide for 16 hours (Figure 6A, lanes 7 and 8).
To correlate these results with promoter occupancy
and transcriptional regulation, we next performed ChIP
experiments with chromatin prepared from BJ-hTERT
fibroblasts treated or not with etopside for 16 hours.
Using high quality ChIP-grade antibodies for MTA3
[22], these experiments demonstrated a strong enrichment
of MTA3 binding onto the HIC1 responsive elements
(HiRE) in the SIRT1 promoter [6, 11] upon induction of
irreparable damage (Figure 6B). Thus, the increase of
HIC1 SUMOylation after a 16 hours etoposide treatment
is nicely correlated with an increase in HIC1-MTA3
interaction, thus favoring the recruitment of MTA3 onto
HIC1 direct target genes. Taken together, these results
demonstrate that HIC1 can interact with the MTA1/MTA2
and MTA3 proteins and hence with a wide variety of
www.impactjournals.com/oncotarget

A short 6 hours etoposide treatment is sufficient
to induce a P53-dependent apoptotic response
HIC1 directly represses SIRT1 transcription to
modulate the P53-dependent apoptotic response to nonrepairable double-strands breaks [6]. Our previous work [8]
[11] and the results reported in this study all emphasize an
increased HIC1 SUMOylation which favors its interaction
with MTA1 or MTA3 in NuRD repressive complexes and
hence enhances its transcriptional repression activity
during the cellular response to irreparable DSBs (Figures 1
and 5–7). However, a long, 16 hours etoposide treatment
could induce a direct transcriptional effect mediated by
HIC1 but also an indirect, “second-wave” effect mediated
by P53 which is acetylated and hence activated through
SIRT1 inhibition by HIC1. Indeed, in these conditions
the pro-apototic Bax, Noxa and PUMA genes and the
anti-apoptotic BCL-2 gene which are not known as direct
target genes of HIC1 but as direct P53 target genes are
activated or repressed, respectively by P53 [6]. To address
this issue, we first performed a pilot time-course response
of BJ-hTert fibroblasts to etoposide. BJ-hTERT cells
2924

Oncotarget

Figure 5: At least two domains in the C-terminal end of MTA1 are implicated in the interaction with HIC1.

(A) Schematic drawing of the human MTA1 protein. The domains identified in MTA1 include the BAH (Bromo-associated homology), the
ELM (Egl-27 and MTA1 homology), the SANT (SW13, ADA2, N-CoR and TF1118) and the GATA-like zinc finger. The region isolated
in the two-hybrid screen with HIC1 is shown with the two first cysteines of the GATA zinc finger not present in the isolated prey, shown
as lower-case letters underlined [11]. The Lysine 509, which is SUMOylated, and the C-terminal SIM motif are also shown with the
hydrophobic core, IVI, underlined and the flanking acidic residues in bold [19]. (B) The SIM (SUMO-interacting motif) in the C-terminal
end of MTA1 is required for its interaction with HIC1. After transfection with the indicated expression vectors, HEK293T cells lysates were
immunoprecipitated with anti-c-myc antibodies. Immunoprecipitated samples [IP c-myc (MTA1)] and 1% of whole cell extracts (Input)
were analyzed by immunoblotting with anti-HIC1 antibodies to detect co-immunoprecipitation. To control for IP efficiency, the membrane
was stripped and probed with anti-MTA1 antibodies (the arrow head indicates a remnant of the HIC1 band). (C) SUMOylation of MTA1
on Lysine K509 is not required for the HIC1-MTA1 interaction. A similar experiment was performed in HEK293T with expression vectors
for wt MTA1 or its non-SUMOylatable version (K509R) and HIC1. In the top panel, *refers to a non-specific band detected. In the bottom
panel, the arrowhead indicates a remnant of the MTA1 band. (D) The HIC1-MTA1 interaction is also strongly reduced by deletion of the
HIC1 SUMOylation motif, ΔMKHEP. A similar Co-IP experiment was realized in HEK293T but with expression vectors for the wt FLAGHIC1 or the FLAG-HIC1 ΔMKHEP deletion mutant and wt MTA1. (E) Interaction of wt and ΔMKHEP HIC1 with endogenous MTA1
proteins in HEK293T cells. Total extracts of HEK293T transfected with the indicated plasmids were analysed by Co-IP with anti-MTA1
antibodies and immunoblotted with MTA1 and FLAG antibodies. Note that the endogenous MTA1 proteins in the immunoprecipitated
materials or in the Inputs migrate as a doublet.
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transfected with Control siRNAs or HIC1 siRNAs were
treated with etoposide for 1, 6 and 16 hours and analyzed
by Western blot for expression of the cell cycle inhibitor
P21CIP1 which is a key factor mediating the P53 response
and also a direct target gene of HIC1 [25]. A similar

induction of P21CIP1 expression is observed after either
6- or 16- hour etoposide treatments as well as a further
increase in siHIC1-treated cells as expected for a HIC1
direct target gene (Supplementary Figure S5A). Thus, a
shorter 6 hours etoposide treatment is sufficient to increase

Figure 6: Irreparable DSBs induced by a 16 hour etoposide treatment lead to an increased interaction of MTA3
with HIC1 and favor its recruitment to the HIC1-response elements in the SIRT1 promoter. (A) Etoposide-induced nonrepairable DSBs lead to an increase of MTA3 interaction with HIC1. HEK293T cells were transfected with the indicated combination
of empty FLAG, FLAG-HIC1, and FLAG-MTA3 expression vectors. 32 hours after transfection cells were incubated for 16 hours with
20 μM etoposide (+) or with DMSO (–) as control. After lysis in IPH buffer, cell extracts were co-immunoprecipitated with anti-MTA3
antibodies. The immunoprecipitates as well as 1% of the whole cell extracts were analyzed by SDS/PAGE and transferred to membranes.
Relevant pieces of the membranes were cut and analyzed by Western blot with anti-FLAG antibodies to detect MTA3 and HIC1. ΔH2AX
and actin levels were used as controls for DSB induction and equal loading, respectively. (B) Etoposide-induced irreparable DSB lead
to an increase of MTA3 recruitment on the HiRE in the SIRT1 promoter. Chromatin was prepared from BJ-hTERT fibroblasts mocktreated with DMSO or treated with 80 uM etoposide for 16 hours to induce irreparable DSB and ChIP experiments were performed with
antibodies against MTA3 or rabbit IgG. The bound material was eluted and analysed by quantitative PCR using primers flanking the HIC1responsive elements (HiRE) in the SIRT1 promoter [6], as previously described [46]. GAPDH was used as a nonbinding control. Values
that are statistically significantly different are indicated by bars and asterisks as follows: *P < 0.05. NS corresponds to values that are not
statistically significantly different.
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HIC1 recruitment to the SIRT1 promoter (Figure 7) and to
induce a P53-dependent apoptotic response while limiting
the induction of indirect HIC1 target genes.

siHIC1 (HIC1-) or sicontrol (HIC1+) oligomers were
subjected to etoposide induced DNA damage. Western blot
analyses confirmed the efficient inactivation of HIC1 by
the siRNA as well as the induction of P53 and p21 after
etoposide treatment (Supplementary Figure S5B). Total
RNA was isolated from treated and untreated cells in
triplicate and subjected to gene expression profiling using
the ILLUMINA HumanHT-12 v4 Expression BeadChip
kit. To identify potential target genes, two normalization
strategies were employed. In the first, HIC1+ and HIC1etoposide treated cells (conditions II and IV) were first
normalized to their untreated counterparts (conditions I and
III) to identify genes that became repressed as a result of

Identification of new potential target genes
regulated by HIC1 SUMOylation
Given our findings of the important role played by
HIC1 SUMOylation in the transcriptional response to
irreparable DSBs, we chose to employ a gene expression
profiling approach to identify candidate genes for HIC1mediated transcriptional repression after the induction
of DNA damage. BJ-hTERT cells transfected with either

Figure 7: HIC1 and MTA1 recruitment to the HIC1-response elements in the SIRT1 promoter is increased upon
induction of non-repairable DSBs. (A) HIC1 recruitment to the HiRE in the SIRT1 promoter in various conditions. Chromatin was

prepared from BJ-hTERT fibroblasts not-treated, mock-treated with DMSO or treated with 80 μM etoposide for various times and ChIP
experiments were performed with antibodies against HIC1 or rabbit IgG. The bound material was eluted and analysed by quantitative PCR
using primers flanking the HIC1-responsive elements (HiRE) in the SIRT1 promoter [6], as previously described [46]. GAPDH was used as
a nonbinding control. (B) Etoposide-induced irreparable DSBs lead to an increase of HIC1 and MTA1 recruitment to the HiRE in the SIRT1
promoter. Chromatin was prepared from BJ-TERT fibroblasts mock-treated with DMSO or treated with 20 mM etoposide for 16 hours to
induce irreparable DSBs and ChIP experiments were performed with antibodies against HIC1, MTA1 or rabbit IgG as described in panel
A). Values that are statistically significantly different are indicated by bars and asterisks as follows: *P < 0.05, **P < 0.01. NS corresponds
to values that are not statistically significantly different.
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DNA damage. In order to determine which of those genes
were candidates for SUMO-HIC1 mediated repression, the
list of repressed genes in HIC1- cells was subtracted from
those repressed in HIC1+ cells yielding 629 genes repressed
in a HIC1 replete context and not in the absence of HIC1
(Figure 8A, solid lines; Supplementary Table S1). In the
second normalization strategy, mRNA expression from
both the HIC1+ and HIC1- BJ-hTERT cells that were treated
with etoposide (conditions II and IV) were compared
back to the HIC1 sufficient untreated cells (condition I).
The transcripts that were significantly repressed in the
HIC1- context were subtracted from those repressed
in the HIC1+ cells leaving 475 genes whose repression

was potentially mediated by HIC1 (Figure 8A, dashed
lines; Supplementary Table S2). The agreement between
the resulting gene lists was substantial with 319 genes
representing the intersection of these gene sets (Figure 8B,
Supplementary Table S3). It is important to note that these
genes likely represent both direct and indirect HIC1mediated transcriptional repression. The union of these
lists (785 genes) was used to identify interaction maps
using Ingenuity Pathway Analysis software. The top
canonical pathway mapped by the repressed gene set was
“Role of BRCA1 in DNA Damage Response”. Measured
by the number of molecules represented, “Cell Death”
and “Cell Cycle” were the top cellular functions identified

Figure 8: Identification of the genes regulated in BJ-hTERT human fibroblasts by HIC1 in the presence and absence
of etoposide to induce irreparable DSB. (A) Schematic drawing of the experimental design of the study and of the 2 normalization

strategies used to identify the genes regulated by HIC1 in the presence and absence of a 6 hours etoposide treatment to induce irreparable
DSBs. Four experimental conditions were used and compared using two different comparison strategies. In the first comparison strategy
(Strategy #1 : normalization of IV to III, shown as black lines), BJ-hTERT siCtrl cells treated with etoposide were compared to control
cells (siCtrl, no etoposide) to define genes repressed by etoposide and thus containing a subset of genes repressed by SUMOylated HIC1.
Then, BJ-hTERT siHIC1 cells treated or not with etoposide were compared to define genes still repressed by etoposide in a HIC1-deficient
context. Subtracting [IV] from [II] yields 629 target genes repressed in response to DSBs and dependent upon HIC1 SUMOylation. In the
second strategy (Strategy #2: normalization of IV to I, shown as dotted lines), BJ-hTERT siCtrl and BJ-hTERT siHIC1 cells, both treated
with etoposide, were each compared to control cells (siCtrl, no etoposide). In that case, subtracting [IV] from [II] yields 475 target genes.
(B) Venn diagrams showing the overlap of the 629 and 475 target genes from the 2 normalization strategies used yields a strong overlap of
319 genes (see text for detail).
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with 80 and 58 genes represented respectively (data not
shown). Since HIC1 SUMOylation increases its interaction
with MTA1, we next compared these HIC1 target genes
with MTA1 target genes obtained through gene profiling
experiments of wt and Mta1–/– murine embryos fibroblasts
(MEFs) [26]. This comparison highlighted 17 genes
(Figure 9A). Among them, CXCl12, EPHA4, LPHN2,
TGFβR3 and TRIB2 were validated by qRT-PCR as
potential target genes regulated by HIC1 SUMOylation.
Indeed, they are activated in siHIC1 BJ-hTERT fibroblasts
as compared to siCtrl cells in control conditions (DMSO)
and further repressed in siCtrl cells treated with etoposide
(Figure 9B). Thus, we were able to place HIC1 and its
interaction with NuRD complexes through its increased
SUMOylation among the canonical pathways responsible
for the transcriptional response to irreparable DSBs
while yielding further potential targets of HIC1 for future
validation.

largest family of zinc-finger transcription factors, can
undergo SUMOylation. KAP1 SUMOylation mediates
its interaction with NuRD complexes owing to a SIM
motif found in the C-terminal part of the ATP-dependent
chromatin remodeling subunit CHD3 [36]. Upon DSB
induction, phosphorylation of KAP1 Ser804 produces
a SIM-like domain which interferes with the KAP1SUMO/SIM-CHD3 interaction thereby causing dispersal
of CHD3/NuRD from the DSBs and chromatin relaxation
allowing repair to occur [37, 38].
In this manuscript, we have studied in-depth the
SUMOylation of the transcriptional repressor HIC1
in various aspects of the DDR to DSBs. Indeed, HIC1
was originally characterized as a tumor suppressor gene
encoding a transcriptional repressor facilitating the P53
dependent apoptotic response [4, 6, 5]. But HIC1 is also
involved in the repair of DSBs since BJ-hTERT fibroblasts
treated for 1 hour with etoposide and siRNAs targeting
HIC1 repairs DSBs less efficiently than cells treated with
control siRNAs [8]. Therefore, the current study nicely ties
together HIC1 and the two major areas of SUMOylation
research, the role of SUMOylation in transcriptional
repression and its role in the DNA damage response
[30, 33]. In that setting, we previously demonstrated
an ATM-dependent increase in HIC1 SUMOylation
favoring the interaction with MTA1, a core component
of NuRD chromatin remodeling complexes in response
to irreparable DSBs induced by a 16 hour etoposide
treatment [8, 11]. On the contrary, HIC1 SUMOylation
remains globally at basal levels when cells are exposed to
etoposide for 1 hour to induce repairable damage, even in
presence of the ATM inhibitor Ku-56933 (Figure 1). To
date the only functions ascribed to HIC1 SUMOylation
are to increase the transcriptional repression potential of a
HIC1-Gal4 chimera in transient luciferase assays [10] and
to enhance the interaction of HIC1 with the corepressor
MTA1 [8, 11]. Even though its SUMOylation levels did
not increase, HIC1 can still be SUMOylated when cells
are exposed to etoposide for 1 hour and SUMOylation
is one of the major post-transcriptional modifications
involved in the DNA damage response [27]. However,
results of the Comet assays performed with the nonSUMOylatable HIC1 E316A strongly argue against a
positive role of HIC1 SUMOylation and hence of HIC1NuRD interactions in the well documented functions
for SUMOylation in DSBs repair: inhibition of local
transcription at DSBs, repression of target genes during the
repair process or heterochromatin relaxation (Figure 10).
In contrast to the obvious lack of necessity for the
cellular response to repairable DSBs demonstrated in this
study, the increase of HIC1 SUMOylation, important for
the response to irreparable damage, has previously been
shown to be dependent on ATM (Figure 3) [8]. We have
further refined this finding by showing that this HIC1
SUMOylation increase is independent of the effector
nucleoplasmic kinase, Chk2 (Figure 4). Since ATM is

DISCUSSION
The cellular response to different types of DNA
damages involves a complex interplay of various posttranslational modifications including phosphorylation
by PIKK kinases, Ubiquitinylation, PARylation and
SUMOylation among many others [27–29]. SUMOylation
is a very dynamic post-translational modification, involved
essentially in regulation of protein-protein interaction and
organization of macromolecular complexes through SIMs
(SUMO-interacting motifs) that allow effector proteins to
engage SUMO-modified substrates [12, 30]. Numerous
proteins modified by SUMOylation have been identified
and many of them are associated with transcriptional
repression [30, 31]. SUMOylation is also a very labile
PTM affecting only a small percentage of target proteins,
the so-called “SUMO paradox” [12] and is thus difficult
to detect. It is also becoming increasingly clear that
SUMOylation plays a key role in the regulation of DNA
damage repair and responses with, for example, an
increased presence of SUMO at sites of DNA damage [27]
and an orchestrated SUMOylation of subsets of chromatin
remodelers to decrease global transcription upon DNA
damage [32, 33]. SUMOylation is also implicated
in another important aspect of the repair process,
determining the kinetics and mechanisms for the repair
of DSBs occurring either in open and transcriptionally
active euchromatin or in highly compacted and
transcriptionally inactive heterochromatin [34, 35]. The
chromatin compaction found in heterochromatin on one
hand protects it from DNA damages but on the other
hand impairs the repair process once the damage occurs.
Therefore, the majority of DSBs in heterochromatin are
repaired with slow kinetics through ATM-dependent
mechanisms of chromatin “relaxation”, as exemplified
by the ATM-mediated phosphorylation of KAP1. KAP1,
the obligate co-repressor for KRAB zinc fingers, the
www.impactjournals.com/oncotarget
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stabilized and activated at chromatin, these results are in
strong agreement with the “on-site modification” model
for SUMOylation [39]. Furthermore, we have shown that
the functionally distinct MTA3 corepressor also interacts
with HIC1 in a SUMOylation-dependant manner. In ChIP
experiments, we also observed an increased binding of
HIC1 to the SIRT1 promoter. This could be explained at

least in part by the increased SUMOylation of HIC1 since
SUMOylation increased the DNA-binding properties of
the BTB/POZ transcriptional repressor PLZF [23, 24] and
the POU transcription factor Oct4 [40]. As a whole, these
results firmly link the increase of HIC1 SUMOylation to
a role in the transcriptional repression of target genes by
NuRD repressive complexes to orchestrate the apoptotic

Figure 9: Identification of target genes potentially regulated in BJ-hTERT human fibroblasts by HIC1 SUMOylation
and MTA1. (A) Venn diagrams showing the overlap of the 475 target genes from the normalization strategy #2 and the 1024 genes

affected by MTA1 knock out in murine embryonic fibroblasts (MEFs) [26]. (B) Validation by qRT-PCR of the microarray data showing
differential regulation of some selected genes in BJ-hTERT cells. RNAs were extracted from BJ-hTERT using the same four experimental
conditions as in the microarrays analyses. Selected genes (CXCl12, EPHA4, LPHN2, TGFβR3 and TRIB2) were analysed by qRT-PCR
analyses and showed the expected differential regulation (see text for detail).The expression of HIC1 and of its direct target genes SIRT1
and P21 were also tested as positive controls.
www.impactjournals.com/oncotarget
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DNA damage response (Figure 10). Two key genes in
this process are SIRT1 [6] and p21 [25]. To have a more
global vision of the HIC1 target genes involved in the
transcriptional DNA damage response to non-repairable
DSBs, we have conducted gene profiling analyses of BJhTERT fibroblasts with or without HIC1 inactivation by
RNA interference and treated or not with etoposide for
6 hours. Through two thorough normalization strategies
we were able to identify 475 genes regulated by HIC1
in an etoposide-dependent manner (Figure 9). In good
agreement with the longstanding role of HIC1 in the
P53-dependent apoptotic response [6] and the importance
of HIC1 SUMOylation in this process as shown by our
previous work [8, 10, 11] and extended in this study,
many of these genes are implicated in cell death and
cell cycle control. Further crossing these 475 genes with
known MTA1 target genes highlighted 17 common genes,
which could be HIC1 direct or indirect target genes.
Among them, we validated by qRT-PCR analyses three
receptors, the Ephrin A4 tyrosine kinase receptor, the
GPCR receptor Latrophilin2 (LPHN2) and the TGF-beta
type III receptor, a membrane proteoglycan that often
functions as a co-receptor with other TGF-beta receptor
superfamily members. Interestingly, we also defined as
potential new HIC1 target genes TRIB2, a pro-apototic-

molecule belonging to the atypical protein kinase family
Tribbles [41] and SDF-1/CXCL12, a chemokine which is
the ligand for the G-protein coupled chemokine (C-X-C
motif) receptors, CXCR4 and CXCR7, the latter being a
direct HIC1 target gene [42, 43].
In conclusion, our work demonstrates that HIC1
SUMOylation is dispensable for DNA DSB repair but
essential as a transcriptional repressor for the apoptotic
response in the case of irreparable DSBs. Further studies
are currently in progress to decipher the functional role of
HIC1 in DNA repair. In particular, we are trying to identify
potential HIC1 PTMs specifically induced when cells are
exposed to repairable DSBs. These analyses would help to
better decipher and understand the contribution of HIC1 to
the repair process.

MATERIALS AND METHODS
Cell lines and transfection
Cos-7, HEK293T and BJ-hTERT cells were
maintained in Dulbecco modified Eagle medium
(Invitrogen) supplemented with 10% fetal calf serum, nonessential amino acids and gentamycin. Cells were cultured
at 37°C in humidified 5% CO2 atmosphere.

Figure 10: HIC1 SUMOylation is dispensable for DNA repair but essential for the transcriptional response to nonrepairable DSBs. (A) Upon induction of repairable DSBS, HIC1 participates in the early steps of the repair process [8] by a mechanism
that still remains to be deciphered. However, this is independent of HIC1 SUMOylation but could be due to other post-translational
modifications. (B) Upon induction of non-repairable DSBs, the activated ATM kinase increases HIC1 SUMOylation which in turn enhances
the binding of HIC1 to its responsive elements (HiRE) in the promoters of target genes (e.g. SIRT1) as well as the interaction of HIC1 with
the MTA1 or MTA3 co-repressors to increase the transcriptional repression of direct target genes.
www.impactjournals.com/oncotarget
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Plasmids and chemicals

FLAG-HIC1 vectors and treated with etoposide 24 hours
later as previously described [8].

The expression vectors for full-length FLAG-HIC1,
the non-SUMOylatable FLAG-HIC1 E316A, for HisSUMO2, Myc-MTA1, the non SUMOylatable Myc-MTA1
K509R and SIM-deficient Myc-MTA1 AAA mutants have
been described previously [8, 10, 19]. The ΔMKHEP
deletion mutant was generated by the two-round PCR
mutagenesis strategy.
Etoposide and the Chk2 inhibitor C3742 (Chk2
inhibitor II hydrate) were purchased from Sigma-Aldrich.
Wortmannin (Calbiochem), a PI3K inhibitor which
also inhibits PIKKs and ATM (KU-55933; Santa Cruz
Biotechnology) and DNA-PKcs (NU-7441, Selleckchem)
inhibitors were dissolved in DMSO and used at a final
concentration of 10 µM. Inhibitors were added to culture
medium 1 hour before subsequent treatments.

Comet assays
Cos7 cells were transfected for 48 h with expression
vectors either for wt FLAG-HIC1 and the empty FLAG
expression vector or for the non-SUMOylatable point
mutant FLAG-HIC1 E316A and analyzed by neutral
Comet assays, as previously described [8, 44]. For each
condition, 2,000 cells were suspended in 80µl of 0.5%
low melting point agarose at 42°C. The suspension was
immediately laid onto a comet slide (TREVIGEN Inc.).
Agarose was allowed to solidify at 4°C for 20 min. The
comet slides were then immersed in prechilled lysis
solution (1.2 M NaCl, 100 mM EDTA, 10 mM Tris, 1%
Triton, pH = 10) at 4°C, for 90 min in the dark. Comet
slides were next placed in a horizontal electrophoresis
unit, and let to equilibrate in electrophoresis buffer (Tris
89 mM, Boric acid 89 mM, EDTA 2 mM, pH8 to detect
double strand breaks) for 10 min at 4°C, in the dark. After
migration (40 V for 25 minutes), the slides were stained
with SYBR green (Molecular Probes-1000X) according to
manufacturer’s recommendations.

Transfection and co-immunoprecipitation
Cells were transfected in Opti-MEM (Invitrogen)
by the PEI method using ExGen 500 (Euromedex) as
previously described with 2.5 µg of DNA corresponding to
the relevant expression vectors or the empty vector used as
control. Cells were transfected for 6 h and then incubated
in fresh complete medium.
For co-immunoprecipitation analyses (Co-IPs),
48 h after transfection, cells were rinsed with cold PBS
and lysed in cold IPH buffer (50 mM Tris, 150 mM
NaCl, 5 mM EDTA, 0.5% NP40, protease inhibitor
cocktail [Roche]). Cell lysates were sonicated briefly and
cleared by centrifugation (14,000 rpm, 4°C, 15 min). The
supernatants were pre-cleared with 15 µl of protein A/G
sepharose beads (Amersham Bioscience) incubating during
1 hour on a rotator at 4°C. Then, lysates were incubated
with 2 µg of antibody on a rotator at 4°C overnight. Later,
20 µl of protein A/G beads were added and incubated
30 min at 4°C. Finally, the beads were washed three times
with IPH buffer. Bound proteins were eluted by boiling in
Laemmli buffer before analyses by SDS/PAGE followed
by immunoblotting.

Quantitative RT-PCR
Total RNA was reverse transcribed using random
primers and MultiScribeTM reverse transcriptase (Applied
Biosystems). Real-time PCR analysis was performed by
Power SYBR Green (Applied Biosystems) in a MX3005P
fluorescence temperature cycler (Stratagene) according to
the manufacturer’s instructions. Results were normalized
with respect to 18S RNA used as an internal control
[45]. The primers used for the qRT-PCR analyses are
summarized in Supplementary Table S4.

Western blotting and antibodies
Proteins were separated by SDS-PAGE and
transferred onto nitrocellulose membranes (GE
healthcare). Western blot analyses were performed as
previously described [8].
Commercial antibodies of the following specificities
were used: FLAG M2 from Sigma; Anti MTA1 (sc-9445
for WB and sc-10813 for IP) from Santa Cruz and Anti
MTA3 (ab87275) from Abcam; γH2AX, H2AX (total),
pS1681ATM, ATM total, DNA-PKcs total, DNA-PKcs
(pS2056) from Abcam, Chk2, pS516Chk2, pT68Chk2
pS20P53 and anti-actin antibodies (sc-1616-R) from
Santa Cruz Biotechnology. The secondary antibodies were
horseradish peroxidase-linked antibodies against rabbit,
rat and mouse immunoglobulins (Amersham Biosciences);
goat immunoglobulins (Southern Biotech).
To analyze the SUMOylation of HIC1 proteins by
Western blotting analyses, transfected HEK293T cells
pelleted by centrifugation were directly lysed in Laemmli

Small interfering RNA
HEK293T cells were reverse-transfected with
Lipofectamine RNAiMax (Invitrogen) according to
manufacturer’s instructions using 10 nM small interfering
RNA targeting Chk2 (Human CHEK2 siGENOMESMARTpool M-003256-06-0005, Dharmacon), ATM
(Human ATM siGENOME siRNA-SMARTpool
M-003201-04-0005, Dharmacon) or a scrambled control
sequence (si Ctrl; siGENOME RISC free control siRNA,
Dharmacon). For DNA-PKcs (referenced as PRKDC), we
prepared a pool with four individual ON-TARGET plus
PRKDC siRNAs (LQ-005030-00-0005, Dharmacon) or
tested these four siRNAs individually [44]. 24 hours after
siRNA transfection, cells were transfected with FLAG or
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Chromatin immunoprecipitation
Human BJ-hTERT fibroblasts were treated with
DMSO or Etoposide for 16 hours, washed with PBS
and resuspended in 0.5 ml PBS for 5 × 106 cells. Then,
cells were fixed by adding formaldehyde to a final
concentration of 1% for 8 min at room temperature. To
stop fixation, glycine was added to a final concentration
of 0.125 M. After 5 min at room temperature, cells were
collected by centrifugation (1500 rpm, at 4°C, 5 min).
The supernatants were removed and we lysed cells
by resuspension in chilled cell lysis buffer for 10 min
on a rotator at 4°C. Then, the samples were pelleted,
resuspended in 200 µl nuclei lysis buffer and sonicated to
chromatin with an average size of 250 bp using a cooling
BioRuptor (Diagenode, Belgium). 20 µg of chromatin was
immunoprecipitated with indicated antibodies and realtime PCR analyses were performed as described [22]. The
primers used for GAPDH, SIRT1 and ATOH1 have been
previously described [46].
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